Navigation Links
Liver cancer incidence lower in patients with nonalcoholic fatty liver disease than hepatitis C
Date:9/27/2011

Patients with non-alcoholic fatty liver disease (NAFLD) with advanced fibrosis or cirrhosis have a lower incidence of liver-related complications and hepatocellular carcinoma (HCC) than patients infected with hepatitis C virus (HCV), according to the prospective study published in the October issue of Hepatology, a journal of the American Association for the Study of Liver Diseases. Patients with both NAFLD and HCV had similar mortality rates.

NAFLD has become the most prevalent cause of chronic liver disease worldwide, with studies reporting up to 30% of the general population and 75% of obese individuals having the disease. A minority of cases develop fibrosis or cirrhosis of the liver, and NAFLD with advanced fibrosis or cirrhosis can lead to hepatic-related complications, HCC, liver failure or death. While the incidence of NAFLD has increased, studies of the natural history of the disease in conjunction with advanced fibrosis or cirrhosis and later outcomes have been limited.

"Our study reports on the long-term morbidity and mortality of NAFLD patients with advanced fibrosis or cirrhosis by prospectively following up cases from four international collaborating hepatology centers," explains lead author Dr. Neeraj Bhala from the University of Oxford in the UK. "Understanding the long term prognosis of NAFLD patients compared with patients affected by other liver diseases such as chronic HCV was an important aspect of our study." Medical evidence suggests that while HCV is currently the leading indication for liver transplantation, affecting more than 5 million individuals in the U.S, HCV incidence has plateaued, while that for NAFLD is on the rise.

In the largest prospective study of participants with advanced fibrosis or cirrhosis to date, the team recruited 247 patients with NAFLD and 264 patients with HCV infection who were not previously treated or were unresponsive to therapy from centers in Australia, Italy, the UK and the USA. Patients in both groups were Child-Pugh class A and had advanced fibrosis (stage 3) or cirrhosis (stage 4) confirmed by liver biopsy at the onset of the study. Follow-up in the NAFLD and HCV groups was a mean of 86 and 75 months, respectively.

Of those patients in the NAFLD group, 19% had liver-related complications and 13% died (or received transplants). Liver-related complications and deaths (or transplants) in the HCV cohort were lower at 17% and 9%, respectively. However, after adjusting for age and gender, the incidence of liver-related complications, including liver cancer, was lower in the NAFLD group compared to the HCV cohort. Researchers found that cardiovascular complications and overall mortality were comparable between the groups, although moderate differences cannot be excluded, highlighting the need for even larger collaborative prospective studies.

In a related editorial published this month in Hepatology, Dr. Mary Rinella with Northwestern University Medical School in Chicago, Illinois said, "The study by Bhala and colleagues expands our knowledge of the natural history of NAFLD and NASH. While HCC was not surprisingly higher in untreated patients with HCV compared to NAFLD, this study highlights the potential of HCC development in non-cirrhotic patients with HCV and NASH. If patients with NAFLD or HCV are likely to develop HCC before the development of cirrhosis, this has tremendous implications for how and when liver cancer screening should begin in patients with liver disease."


'/>"/>

Contact: Dawn Peters
healthnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. MarquisNet Co-Location Agreement with MessageBroadcast Helps Message Delivery Provider Expand World-Class Network
2. Launch of On Time Air Filters: Home Air Filter Delivery Service Helps Homeowners Replace All-Important Home HVAC Filters On Time
3. Smithfield, United Food and Commercial Workers Union, and Food Networks Paula Deen to Deliver 150,000 Servings of Protein to San Francisco Food Bank
4. WellPoint/Blue Cross Liver Transplant Denial Trial Starts Monday
5. Home Care Delivered, Inc. Launches a New Vacuum Therapy Category to Service Patients with Erectile Dysfunction
6. WellPoint/Blue Cross Liver Transplant Denial Trial Begins Today, Illustrates Need for Toughening of White House Reform Plan
7. GE Healthcare, Intel and Mayo Clinic explore new models of health care delivery
8. New Heart CT Scans Deliver Far Less Radiation: Study
9. International Medical Corps and Agility Partner in Delivering Quake Relief to Haiti
10. Gourmet Diet Delivery Unites with First Lady's Battle Against Obesity The Fresh Diet Begins Delivering Meals to DC
11. Reliable biomarkers needed for early detection of liver cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Backed by decades of ... each job, ensuring the best suited solution to meet regulatory requirements. Their professional ... their lab in Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of medical ...
(Date:5/24/2016)... ... May 24, 2016 , ... Eggsurance, the first ... relaunch of its community and education hub for women considering fertility preservation, as ... create a safe and welcoming place for women to find cycle buddies, get ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... advancing the science and clinical practice of radiosurgery, is recognizing five medical residents ... radiosurgery (SRS) and stereotactic body radiotherapy (SBRT). The awards will be presented at ...
(Date:5/24/2016)... ... May 24, 2016 , ... The ... 9.3 million people, or 10% over last year, according to data in the ... group policies was comparatively stable, with a slight decrease in risk-based groups and ...
(Date:5/24/2016)... ... May 24, 2016 , ... Bio-Logic ... specialist for forty years and a trainer for Ageless Grace ( http://www.agelessgrace.com ) ... Talk Show on May 16, 2016. , Formerly a Northwestern University Literature Professor, ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... , May 23, 2016 ... for the treatment of cancer and orphan genetic diseases, ... up to $4.4 million from the Israel Innovation Authority ... Israeli Ministry of Economy and Industry. The mission of ... entrepreneurship in various industries, including science and technology, while ...
(Date:5/23/2016)... May 23, 2016   Purdue Pharma L.P. ... an agreement with Egalet Corporation and Acura Pharmaceuticals, ... part of the agreement the companies will exchange ... all three companies to develop and sell several ... "This agreement reflects the commitment of Purdue Pharma ...
(Date:5/20/2016)... , May 20, 2016 ... 2016 to Medical Devices of its online business ... survey on the current state of the Titrator ... the industry like definitions, classifications, Specifications, applications and ... manufacturing process like Raw Material Suppliers, Equipment Suppliers, ...
Breaking Medicine Technology: